NREP
NEW REPRESENTATIVE AT IB RECEIVED
23/07/2026
Voltar para busca
Dado oficial do USPTO
NAVIGNOSTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
NAVIGNOSTICS
ST13
US500000079395780Classe
5, 10, 42
Pedido
79395780
Registro
7862453
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
27
Atualização mais recente
23/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10, 42
Data de depósito
15/02/2024
Data de registro
15/07/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
15/07/2025
Última transação
23/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
84
Localização do titular
CH
Examinador
EDWARDS, ALICIA COLLINS
Unidade examinadora
M60
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Navignostics AG
A. J. (pessoa física)
Representantes
Nicholas D. Wells Legends Law Group, PLLC
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Reactants for medical diagnosis; diagnostic preparations for medical purposes; diagnostic reagents for medical or veterinary use in in vitro diagnosis; reactants for medical diagnosisparticularly for usage with spatial single-cell proteomics reagents for diagnostic tests for medical use; diagnostic test reagents for veterinary use; diagnostic preparations for medical use; diagnostic radiopharmaceutical preparations for medical purposes; diagnostic substances for medical use; pharmaceutical productsmedical and veterinary preparationspharmaceutical preparations for use in the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations for the diagnosis and treatment of cancer; pharmaceutical preparations for the diagnosis of diseases; diagnostic pharmaceutical preparations; pharmaceutical preparations for individual medical diagnosis; medical test kits comprising pharmaceutical preparations for cancer therapy; medical test kits comprising pharmaceutical preparations for use in oncology for cancer screening; medical test kits comprising pharmaceutical preparations for cancer diagnosis; medical test kits comprising pharmaceutical preparations for individual medical diagnosis in the field of protein imaging; diagnostic test kits comprising pathology slides for testing tissue samples; test kits for use in oncology comprising sample tubes for testing tissue samples; diagnostic test kits comprising laboratory equipment for sample preparationprocessing and storage for cancer diagnosis; diagnostic test kits for individual medical diagnosis comprising sample collection equipment for tumour analysis
Classe 10
Apparatus for tumour diagnosisImaging Mass Cytometry (IMC) apparatus; medical apparatusspectrometers for machine learning-based spectrum analysis of human blood plasma; Multiplex protein imaging scanners for medical diagnosis; apparatus for clinical diagnosisdigital imaging device; spectrum analysers for use in medical diagnosis; trace material analysers for medical use in diagnosis; apparatus used in implementing diagnosis tests designed to detect abnormal genetic mutations in proteinsspatial proteomics tools; medical test kits for cancer testing; diagnosticexaminationmonitoring equipmentmultiplex protein imaging equipment; medical test kits comprising tissue sampling equipment for the use in oncology for cancer screening; medical test kits for cancer diagnosis; medical test kits comprising tissue analysis tools for individual diagnosis in the field of cancer therapy
Classe 42
Scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of proteomics; oncological research; medical research in the field of oncological diagnostics; computer programming for medical data analysis for cancer diagnostics; development of personalized diagnostics products in the nature of data samplingimaging and analysis for cancer treatment; software-as-a-service (SaaS) featuring software for use in cancer diagnosis; platform-as-a-service (PaaS) featuring software for use in cancer diagnosis; software-as-a-service (SaaS) featuring software for cell analysis for use in oncology; platform-as-a-service (PaaS) featuring software for cell analysis for use in oncology; software-as-a-service (SaaS) featuring software for medical and scientific research in the field of cancer treatment and diagnosis; platform-as-a-service (PaaS) featuring software for medical and scientific research in the field of cancer treatment and diagnosis; software-as-a-service (SaaS) featuring software using machine learning in the field of medical diagnosis and researchparticularly for cancer researchtreatment and diagnosis; platform-as-a-service (PaaS) featuring software using machine learning in the field of medical diagnosis and researchparticularly for cancer researchtreatment and diagnosis; computer programming in the field of using machine learning regarding medical diagnosis and researchparticularly for cancer researchtreatment and diagnosis; software as a service (SaaS) featuring software for the analysis of medical dataparticularly for cancer researchtreatment and diagnosis; software-as-a-service (SaaS) featuring software for the analysis of medical dataparticularly for cancer researchtreatment and diagnosis; platform-as-a-service (PaaS) featuring software for the analysis of medical dataparticularly for cancer researchtreatment and diagnosis; software as-a-service (SaaS) featuring software for the digital representation of tumours and tumour features; platform-as-a-service (PaaS) featuring software for the digital representation of tumours and tumour features; software as-a-service (SaaS) featuring software for high-resolution digital image representation of the molecular composition of cellular anomalies; platform-as-a-service (PaaS) featuring software for high-resolution digital image representation of the molecular composition of cellular anomalies; software as-a-service (SaaS) featuring software for high-resolution digital image representation of digital tumours; platform-as-a-service (PaaS) featuring software for high-resolution digital image representation of digital tumours; cancer diagnosis research
Publicações
Histórico de despachos e eventos da marca no USPTO.
27 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/04/2026
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
06/02/2026
XXCR
GENERIC MADRID TRANSACTION CREATED
05/02/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
31/10/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
15/10/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
15/10/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
15/10/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
15/07/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
15/07/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
27/05/2025
PUBO
PUBLISHED FOR OPPOSITION
27/05/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/05/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/04/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/03/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/03/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/03/2025
RFNT
REFUSAL PROCESSED BY IB
12/10/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
23/09/2024
RFRR
REFUSAL PROCESSED BY MPU
23/09/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
20/09/2024
CNRT
NON-FINAL ACTION WRITTEN
19/09/2024
DOCK
ASSIGNED TO EXAMINER
06/09/2024
CHLD
CHANGE OF OWNER RECEIVED FROM IB
09/08/2024
MAFR
APPLICATION FILING RECEIPT MAILED
22/05/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
22/05/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
16/05/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NAVIGNOSTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.